➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Boehringer Ingelheim
Mallinckrodt
Medtronic
Moodys

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for CB-839

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CB-839?

CB-839 is an investigational drug.

There have been 21 clinical trials for CB-839. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2017.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Novotech (Australia) Pty Limited.

There are sixteen US patents protecting this investigational drug and one hundred and twenty-four international patents.

Recent Clinical Trials for CB-839
TitleSponsorPhase
Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy SubjectsNovotech (Australia) Pty LimitedPhase 1
Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy SubjectsCalithera Biosciences, IncPhase 1
A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCCalithera Biosciences, IncPhase 2

See all CB-839 clinical trials

Clinical Trial Summary for CB-839

Top disease conditions for CB-839
Top clinical trial sponsors for CB-839

See all CB-839 clinical trials

US Patents for CB-839

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CB-839   Get Started for $10 Combination therapy with glutaminase inhibitors Calithera Biosciences, Inc. (South San Francisco, CA)   Get Started for $10
CB-839   Get Started for $10 Compositions and methods of treating cancer harboring PIKC3A mutations Case Western Reserve University (Cleveland, OH)   Get Started for $10
CB-839   Get Started for $10 Combination therapy with glutaminase inhibitors and immuno-oncology agents Calithera Biosciences, Inc. (South San Francisco, CA)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
Express Scripts
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.